Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | IDH1 | O75874 | 2/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6213205 | 0.80 | TSHR (0.66) | TSHRIDH1SRCKDM4ENPC1 | |
| SCHEMBL31641414 | 0.78 | TSHR (0.56) | TSHRLTA4HSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL2319042 | 0.78 | MEN1 (0.56) | TSHRLTA4HSMN1; SMN2LMNAPTGS2 | |
| SCHEMBL4507082 | 0.78 | SMN1; SMN2 (0.48) | TSHRLTA4HSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL2257933 | 0.78 | LTA4H (0.50) | TSHRLTA4HSMN1; SMN2PTGS2KDM4E | |
| SCHEMBL12439998 | 0.77 | MCHR1 (0.56) | LTA4HCYP2D6PTGS2SRC | |
| SCHEMBL1306764 | 0.76 | IDH1 (0.53) | CYP2D6LMNAIDH1KDM4E | |
| SCHEMBL12113522 | 0.76 | TSHR (0.53) | TSHRLTA4HSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL12120425 | 0.76 | CYP1A2 (0.54) | TSHRLTA4HSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL1307575 | 0.76 | TSHR (0.53) | TSHRLTA4HSMN1; SMN2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | TSHR 2154/4885LTA4H 2399/4885SMN1; SMN2 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.